Anterior gradient protein 3 is associated with less aggressive tumors and better outcome of breast cancer patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F15%3A%230000627" target="_blank" >RIV/00209805:_____/15:#0000627 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.2147/OTT.S82235" target="_blank" >http://dx.doi.org/10.2147/OTT.S82235</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2147/OTT.S82235" target="_blank" >10.2147/OTT.S82235</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Anterior gradient protein 3 is associated with less aggressive tumors and better outcome of breast cancer patients

Popis výsledku v původním jazyce

Anterior gradient protein (AGR) 3 is a highly related homologue of pro-oncogenic AGR2 and belongs to the family of protein disulfide isomerases. Although AGR3 was found in breast, ovary, prostate, and liver cancer, it remains of yet poorly defined function in tumo-rigenesis. This study aimed to determine AGR3 expression in a cohort of 129 primary breast carcinomas and evaluate the clinical and prognostic significance of AGR3 in these tumors. The immunohistochemical analysis revealed the presence of AGR3staining to varying degrees in 80% of analyzed specimens. The percentage of AGR3-positive cells significantly correlated with estrogen receptor, progesterone receptor (both P,0.0001) as well as low histological grade (P=0.003), and inversely correlatedwith the level of Ki-67 expression (P,0.0001). In the whole cohort, AGR3 expression was associated with longer progression-free survival (PFS), whereas AGR3-positive subgroup of low-histological grade tumors showed both significantly long

Název v anglickém jazyce

Anterior gradient protein 3 is associated with less aggressive tumors and better outcome of breast cancer patients

Popis výsledku anglicky

Anterior gradient protein (AGR) 3 is a highly related homologue of pro-oncogenic AGR2 and belongs to the family of protein disulfide isomerases. Although AGR3 was found in breast, ovary, prostate, and liver cancer, it remains of yet poorly defined function in tumo-rigenesis. This study aimed to determine AGR3 expression in a cohort of 129 primary breast carcinomas and evaluate the clinical and prognostic significance of AGR3 in these tumors. The immunohistochemical analysis revealed the presence of AGR3staining to varying degrees in 80% of analyzed specimens. The percentage of AGR3-positive cells significantly correlated with estrogen receptor, progesterone receptor (both P,0.0001) as well as low histological grade (P=0.003), and inversely correlatedwith the level of Ki-67 expression (P,0.0001). In the whole cohort, AGR3 expression was associated with longer progression-free survival (PFS), whereas AGR3-positive subgroup of low-histological grade tumors showed both significantly long

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

10608 - Biochemistry and molecular biology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

OncoTargets and therapy

ISSN

1178-6930

e-ISSN

—

Svazek periodika

8

Číslo periodika v rámci svazku

June

Stát vydavatele periodika

NZ - Nový Zéland

Počet stran výsledku

10

Strana od-do

1523-1532

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-84934273566